AOL Money & Finance

mergers posts

Feed

Google gets hungry for M&A deals

While the tech sector has held up fairly well during the economic downturn, the dealmaking has lagged. But lately, there has been an uptick activity, such as from companies like Dell (NASDAQ: DELL) and Cisco (NASDAQ: CSCO).

Well, according to Reuters, it also looks like Google (NASDAQ: GOOG) is setting its sights on mergers and acquisitions (M&A).

Continue reading Google gets hungry for M&A deals

Private equity biz back in action

Up until the credit crisis, private equity firms had it made. They had plenty of leverage to play with and could load up their acquisition targets with it. So, they could realize a fantastic return on equity, mitigate their own risks, and show that they were the studs of the Street.

Then, all that went away. Credit markets dried up, and private equity companies lost their acquisition fuel. The numbers aren't as big as they used to be, but it looks like the private equity market is back in action.

Continue reading Private equity biz back in action

Some big names set new 52-week highs Tuesday: WAG, ACS, WYE ...

new 52 week highsAll three of the major indexes finished Tuesday in the red, but there were several big names that moved up to new 52-week highs in Tuesday's trading.

Walgreen Co. (NYSE: WAG): The drugstore giant had a really good day on Wall Street after posting better than expected earnings in the morning before the market opened. The company posted earnings of 44 cents per share versus analyst estimates of 39 cents. The stock set a new 52-week high of $38.44 and closed the day up 9.2% at $37.35.

Continue reading Some big names set new 52-week highs Tuesday: WAG, ACS, WYE ...

Google's hungry, looking for a new company every month

Some people join wine-of-the-month clubs. There are plenty of other programs out there, too, where your credit card is hit every month, and your purchase is sent to you directly. If only such programs were available for Google (NASDAQ: GOOG). . . .

The company's CEO, Eric Schmidt, said Wednesday that Google plans to pick up a small company a month as a way to get its acquisition head back in the game. With the worst of the recession behind us, Google believes, this is a great way to get moving.

Continue reading Google's hungry, looking for a new company every month

Yahoo! seeks to unload small biz assets

Since coming on board Yahoo! (NASDAQ: YHOO) early this year, Carol Bartz has wasted little time in making changes. Part of the strategy is to get the company more focused.

So, it looks like Yahoo! is in the process of selling its small business unit. All in all, it's a good asset, with web hosting, domain name services, and merchant accounts. The deal may also include the HotJobs division.

Continue reading Yahoo! seeks to unload small biz assets

PetroChina's sugar daddy gets $30 billion for takeovers

As the dollars keep piling up in China, there is a need to put the money to work. So how about oil? No doubt, China needs this vital commodity as its economy continues to grow at a rapid clip. Consider that the country imports roughly 3.6 million barrels of oil a day -- and this will inevitably increase in the coming years.

To gear up for things, China National Petroleum Corp. (CNPC) -- which is the parent company of PetroChina (NYSE: PTR) -- secured a $30 billion loan from the Chinese government. Apparently, the interest rate was fairly low (the loan term is five years). And, yes the money will be used to buy up energy assets across the globe.

Continue reading PetroChina's sugar daddy gets $30 billion for takeovers

Kraft wants to eat Cadbury for $16.7 billion

Over the past year, M&A has been on a starvation diet. Then again, with a terrible recession and credit crunch, what do you expect?

Yet, while it is still toot soon to tell, there are signs that things are beginning to improve. Just look at what's cooking between Kraft Foods (NYSE: KFT) and Cadbury (NYSE: CBY). Both global giants are involved in, well, an M&A food fight.

Continue reading Kraft wants to eat Cadbury for $16.7 billion

Wyeth (WYE) shareholders approve sell to Pfizer (PFE)

Weth Pfizer mergerThe mega pharmaceutical merger between Wyeth (NYSE: WYE) and Pfizer (NYSE: PFE) is one step closer to becoming official today after overwhelming approval by Wyeth shareholders.

The shareholder vote to sell Wyeth to Pfizer was not even close. Around 98% of shareholders voted to approve the sale, which is expected to happen by the end of the year.

Continue reading Wyeth (WYE) shareholders approve sell to Pfizer (PFE)

M&A plunges, investment banks find money elsewhere

Mergers and acquisitions aren't delivering the fees that investment bankers used to enjoy, but fortunately, the money's coming from elsewhere. Data from Thomson Reuters reports a 29% increase in capital markets and M&A fees for the first time in more than a year. Share sales (e.g., rights offerings) were where dealmakers found the action. In the shrinking M&A space, Morgan Stanley (NYSE: MS) has taken the lead spot.

Since there are fewer banks in the marketplace than there were a year ago -- and they have less money -- the capital is starting to come from elsewhere. Because they aren't lending at their previous pace, companies are issuing bonds and equity to replenish their coffers. Pfizer (NYSE: PFE), for example, raked in more than $23 billion from the bond market to fund its acquisition of Wyeth (NYSE: WYE), and Roche nabbed Genentech with the help of a $30 billion debt issuance.

Continue reading M&A plunges, investment banks find money elsewhere

PepsiCo Inc. (PEP) bids for bottlers as earnings edge lower

PepsiCo Inc. (PEP) TruckWe're in the heat of earnings season, with many of the top 100 S&P 500 companies reporting this week. One name that slightly fizzled at its earnings report today was PepsiCo Inc. (NYSE: PEP), which announced first-quarter net results of $1.14 billion, or 72 cents per share, a 0.9% decline from previous year's levels.

On the plus side, the per-share result was a nickel better than analysts were expecting, according to Thomson Reuters. Revenue, on the other hand, slipped 0.8% lower to $8.26 billion, falling shy of expectations for $8.28 billion.

While the numbers didn't exactly wow the Street (PEP shares are slightly lower in early trading), they also didn't illustrate a significant fall-off from the previous year, despite company warnings that the first half of 2009 would face challenging year-over-year comparisons amid rising commodity costs and shifting foreign exchange rates.

Continue reading PepsiCo Inc. (PEP) bids for bottlers as earnings edge lower

Dow Chemical, Rohm & Haas make nice in a $15 billion deal

With litigation, it seems that the winners are usually the attorneys. Perhaps this is one of the key reasons that Dow Chemical (NYSE: DOW) and Rohm and Haas Co (NYSE: ROH) agreed to come back to the table and find a way to strike a merger. If not, both parties were on a destructive path to an unpredictable trial.

Interestingly enough, the new terms of the deal reinstate the $78 purchase price, but, of course, there are some wrinkles. The Haas Family Trust and Paulson & Co. will get as much as $3 billion preferred stock in Dow. This will be a much-needed infusion of capital.

Continue reading Dow Chemical, Rohm & Haas make nice in a $15 billion deal

Newmont strikes a deal

This post was written by Minyanville contributor Lance Lewis.

Just after the close yesterday, Newmont Mining (NYSE: NEM) guided up 2009 production and guided 2009 cash costs lower. NEM also announced that it would be purchasing the remaining interest in its majority owned Boddington Mine from Anglogold Ashanti (NYSE: AU) (which equates to 6.6 mln reserve ounces). That's an increase of 8 percent in NEM's Proven & Probable (P&P) reserves at a price tag of $1.2 bln, which will be raised via an equity offering of 19 mln shares.

Based on NEM's 441 mln shares outstanding, we're looking at dilution of just over 4 percent. Thus, in theory, the deal is not even dilutive, given the 8 percent increase in P&P reserves that the company is acquiring with only a 4 percent dilution in equity. Based on what I have seen so far, this looks like a spectacular deal for NEM.

Continue reading Newmont strikes a deal

Dow Chemical's botched M&A experiment

Back in July, Dow Chemical Co. (NYSE: DOW) agreed to pay $15.4 billion for Rohm & Haas Co. (NYSE: ROH), a top specialty chemicals operator. At the time, it looked like a sign that confidence was coming back into the system.

But, of course, the smart money was proved wrong – once again -- as the deal fell apart. So, this week Rohm & Haas has filed a suit against Dow to force the deal to happen. You see, the deal was supposed to close Monday.

The legal action rattled investors: On Monday, Dow's stock fell 7.61% to $13.24 and Rohm & Haas' stock was down 13.25% to $57.10.

Continue reading Dow Chemical's botched M&A experiment

Mergers not heaven sent: Citi, GM, Chrysler, Sirius, AOL, Yahoo!, Microsoft

Almost two years ago I posted a downbeat opinion about a merger that went through and one that did not. However the latter is being discussed again, unbelievable! SEE: GM/Chrysler or Sirius/XM: Two losers don't equal a winner.

In the story I rant about all the things that would improve General Motors (NYSE: GM) and where it is lacking -- noting that being bigger and having more models, less focus and more debt, are not among them. Eventually Cerberus made the big bet and lost. You can be sure they would like to play that hand over again.

Now all three U.S. car companies are in trouble with billions of dollars of losses and huge debt overhangs. All three begged for, and received some amount of federal relief and will need more to sustain themselves though 2009 as it proves to be every bit as tough as 2008 was. Despite everything, GM and Chrysler have been pondering a merger again. BAD IDEA! GM does not need the distraction, they need more focus -- nothing but intense focus!

Continue reading Mergers not heaven sent: Citi, GM, Chrysler, Sirius, AOL, Yahoo!, Microsoft

Don't sell your Genentech (DNA) stock just yet

After the initial rebuff of Swiss-based pharmaceutical giant Roche's offer to acquire the 44% of Genentech (NYSE: DNA) stock Roche does not currently own, DNA is coyly encouraging the completion of a deal at a higher price.

Genentech is among the leading biotech companies in the world. It is engaged in the discovery, development, manufacturing and commercialization of pharmaceutical products intended for treatment of previously untreatable illnesses.

In 1990, Roche acquired a 56% stake in the company. Since that time, the relationship between the two companies has been a model for similarly structured combinations.

Roche's offer of $89 per share for DNA was characterized by DNA as significantly undervaluing the company.

But this was hardly a "hit the road, Jack" response. DNA's board of directors has been encouraging the two sides to continue discussions, and recent comments suggest that the deal could come together soon.

Continue reading Don't sell your Genentech (DNA) stock just yet

Next Page >

Symbol Lookup
IndexesChangePrice
DJIA+17.4610,023.42
NASDAQ+7.122,112.44
S&P 500+2.671,069.30

Last updated: November 08, 2009: 04:31 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

WalletPop Headlines

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance